H M Sebitloane1, J Moodley, T M Esterhuizen. 1. Department of Obstetrics and Gynecology and Women's Health and HIV Group, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. sebitloanem@ukzn.ac.za
Abstract
OBJECTIVE: The purpose of this study was to determine the effect of intrapartum prophylactic antibiotics in the prevention of postpartum sepsis in laboring women who were infected with HIV. STUDY DESIGN: In a double-blind, randomized trial that was conducted in Durban (South Africa), pregnant women who were infected with HIV in whom vaginal delivery was anticipated were randomized to receive either a single dose of cefoxitin (2 g) or placebo intrapartum. Signs of sepsis were evaluated within 72 hours and at 1 and 2 weeks postpartum. RESULTS: Of the 424 women who were enrolled, 213 women receivedcefoxitin, and 211 women received placebo. Both groups were comparable in all baseline parameters. The overall sepsis rate was 19% (40/211 women) in the placebo group and 16.9% (36/213 women) in the cefoxitin group (P = .581). There was a 53% reduction in risk of postpartum endometritis in the cefoxitin group (95% confidence interval, 0.24-0.9). CONCLUSION: The use of prophylactic intrapartum cefoxitin in HIV-infected women reduces the risk of postpartum endometritis.
RCT Entities:
OBJECTIVE: The purpose of this study was to determine the effect of intrapartum prophylactic antibiotics in the prevention of postpartum sepsis in laboring women who were infected with HIV. STUDY DESIGN: In a double-blind, randomized trial that was conducted in Durban (South Africa), pregnant women who were infected with HIV in whom vaginal delivery was anticipated were randomized to receive either a single dose of cefoxitin (2 g) or placebo intrapartum. Signs of sepsis were evaluated within 72 hours and at 1 and 2 weeks postpartum. RESULTS: Of the 424 women who were enrolled, 213 women received cefoxitin, and 211 women received placebo. Both groups were comparable in all baseline parameters. The overall sepsis rate was 19% (40/211 women) in the placebo group and 16.9% (36/213 women) in the cefoxitin group (P = .581). There was a 53% reduction in risk of postpartum endometritis in the cefoxitin group (95% confidence interval, 0.24-0.9). CONCLUSION: The use of prophylactic intrapartum cefoxitin in HIV-infectedwomen reduces the risk of postpartum endometritis.
Authors: Said Aboud; Gernard Msamanga; Jennifer S Read; Lei Wang; Chelu Mfalila; Usha Sharma; Francis Martinson; Taha E Taha; Robert L Goldenberg; Wafaie W Fawzi Journal: Int J Gynaecol Obstet Date: 2009-08-28 Impact factor: 3.561
Authors: Lisa M Bebell; Joseph Ngonzi; Mark J Siedner; Winnie R Muyindike; Bosco M Bwana; Laura E Riley; Yap Boum; David R Bangsberg; Ingrid V Bassett Journal: AIDS Care Date: 2018-02-16
Authors: Tamil Kendall; Isabella Danel; Diane Cooper; Sophie Dilmitis; Angela Kaida; Athena P Kourtis; Ana Langer; Ilana Lapidos-Salaiz; Eva Lathrop; Allisyn C Moran; Hannah Sebitloane; Janet M Turan; D Heather Watts; Mary Nell Wegner Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: G Carosi; P Nasta; S Fiore; A Matteelli; R Cauda; E Ferrazzi; E Tamburrini; V Savasi; T Bini; M Ravizza; A Bucceri; F Vichi; R Murri; F Mazzotta; A d'Arminio Monforte Journal: Infection Date: 2009-03-23 Impact factor: 7.455